Story perspectives

Regeneron to Acquire 23andMe for $256 Million Amid Bankruptcy

5/20/2025

50 11

Summary

Story summary

Regeneron Pharmaceuticals plans to acquire 23andMe for $256 million, gaining genetic data from 15 million customers.
This acquisition aims to boost Regeneron's drug discovery while adhering to 23andMe's privacy policies.
23andMe filed for bankruptcy in March due to a data breach affecting nearly 7 million users.
The deal awaits U.S. Bankruptcy Court approval, with a decision anticipated on June 17.
Regeneron will not take over 23andMe's telehealth service, Lemonaid Health, which will be discontinued.

History

Historical Context

Regeneron's acquisition of 23andMe echoes a historical trend in biotechnology, where companies seek genetic data to enhance drug discovery. Similar to Genentech's early focus on targeted therapies, Regeneron aims to leverage genetic insights for innovative treatments, reflecting the industry's ongoing evolution toward personalized medicine.

1 of 2

Story summary

Regeneron Pharmaceuticals plans to acquire 23andMe for $256 million, gaining genetic data from 15 million customers.
This acquisition aims to boost Regeneron's drug discovery while adhering to 23andMe's privacy policies.
23andMe filed for bankruptcy in March due to a data breach affecting nearly 7 million users.
The deal awaits U.S. Bankruptcy Court approval, with a decision anticipated on June 17.
Regeneron will not take over 23andMe's telehealth service, Lemonaid Health, which will be discontinued.

1 / 2